Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$201.3 million.

  • Dianthus Therapeutics' Cash from Investing Activities rose 2239.67% to -$201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.1 million, marking a year-over-year increase of 3265.18%. This contributed to the annual value of -$286.8 million for FY2024, which is 151614.58% down from last year.
  • Per Dianthus Therapeutics' latest filing, its Cash from Investing Activities stood at -$201.3 million for Q3 2025, which was up 2239.67% from $26.4 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Cash from Investing Activities peaked at $26.4 million during Q2 2025, and registered a low of -$259.4 million during Q3 2024.
  • Its 4-year average for Cash from Investing Activities is -$32.4 million, with a median of -$6.9 million in 2022.
  • In the last 5 years, Dianthus Therapeutics' Cash from Investing Activities soared by 1704883.72% in 2023 and then tumbled by 215435.9% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Cash from Investing Activities (Quarter) stood at -$12.7 million in 2022, then soared by 34.96% to -$8.2 million in 2023, then crashed by 180.56% to -$23.1 million in 2024, then tumbled by 770.94% to -$201.3 million in 2025.
  • Its Cash from Investing Activities stands at -$201.3 million for Q3 2025, versus $26.4 million for Q2 2025 and $14.8 million for Q1 2025.